XTL Biopharma files to raise $40m on Nasdaq
The smartphone has built-in sensors for monitoring heart rate, pulmonary function, blood sugar levels, body temperature and more.
Medical monitor developer LifeWatch AG (SWX:LIFE) has launched the world's first medical smartphone, for Android-powered devices. The smartphone has built-in sensors for monitoring heart rate, pulmonary function, blood sugar levels, body temperature and galvanic skin response (which measures psychological pressure), and other physiological variables. The system can also measure blood pressure with an attached sleeve, and can analyze blood samples.
LifeWatch has developed a range of wireless monitoring devices for emergency rooms and medical services, as well as for personal use, but this is the first time that it has combined these capabilities on a smartphone. Chinese branded mobile phone manufacturer TechFaith Wireless Communication Technology Ltd. (Nasdaq: CNTF) will manufacture the platform for LifeWatch.
LifeWatch develops the medical applications hardware and software that connects the hardware with the smartphone's systems. A German company is responsible for the design. LifeWatch invested several million dollars in the product.
The mobile-health interface is a hot development field in the world. There are various devices, not mobile phones, which collate and transmit medical data, and present them to users, and there are medical mobile apps for managing fitness, medication regimes, and even skin cancer diagnosis by photo analysis. There are also companies developing proprietary sensors for measuring a single medical variable, such as blood glucose levels or heartbeat, for integration with smartphones.
"Globes": Who is the medical smartphone intended for?
LifeWatch chairman and CEO Dr. Yacov Geva: "It is first of all intended for health-conscious consumers who have already recovered from, or are suffering from a chronic medical condition. At an advanced age, we're all suddenly liable to feel poorly in the middle of the day. With this phone, all the basic measurements are available to us. For patients, it enables effective management of their illness."
The device is not designed to diagnose heart attacks, but can monitor irregular heartbeat.
Is the device open to other medical devices and medical apps?
LifeWatch Technologies CEO Yair Tal: "That's the device's secret. Everything is inside, including medical apps, such as nutrition management, pedometer, and medication reminder. These already exist on the device and interface with data collected by us. Any app can be downloaded to the device, but there is no flow of data collected by the device to other apps. At the moment, there isn't an interface with other devices - there's no need for it."
To whom is the data produced by the smartphone sent?
Geva: "Where we operate emergency call centers, the data can be sent there. We currently have three call centers in the US, and we will establish a service in Israel to provide response to users of this product. That's part of our uniqueness as a company, which enables us to market this device. It is also possible to send the data to the patient's doctor and to an insurance company, but the data is primarily intended for the customers who are our target audience."
What regulations does this device require?
"The approval of health authorities is required as for any medical diagnostic device. We believe that we will obtain EU CE Mark certification by the end of this year and US Food and Drug Administration (FDA) approval the following year. It is already possible to market the device in Israel."
Aren't you worried about the rapid change in mobile phones?
"Progress in the mobile field is rapid, which is why we're readying to launch a device with new sensors and innovative capabilities in six to nine months. "
To get people to buy this device, you'll have to cause them to forego a device that is considered fun, such as the iPhone, for a device that marks them as sick. What target audience is so health conscious that it will do that?
"The product is a full telephone, which is intended for an audience that puts its health first. It is also possible to download apps onto it. We're in talks with mobile carriers in Israel and other countries to market the device through them.
LifeWatch's share price fell 2.2% in morning trading in Zurich today to CHF 7.51, giving a market cap of CHF 100 million.
Published by Globes [online], Israel business news - www.globes-online.com - on July 4, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
You comment was recieved and soon will be published.
Load more comments
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.